Aquila Diagnostic Systems Inc. to Present at Venture Summit West
Aquila Diagnostics is pleased to announce that has it been selected to present at the third annual Venture Summit West in Mountain View California on February 28-March 1.
Aquila Diagnostic Systems Inc. Raises $1.75 Million Investment in Series A Financing
June 16, 2016 - Aquila Diagnostic Systems Inc., announces the closing of a $1.75 million Series A financing round with Benslie International Ltd.
Aquila Diagnostic Systems Inc. is a privately held Canadian company commercializing its innovative Accutas solution for a point-of-care molecular (DNA/RNA) diagnostic testing system. The patented Accutas solution provides low cost, laboratory quality diagnostics at the point-of-care, eliminating cost and inconvenience of waiting days or weeks for laboratory results to be returned and the subsequent follow-up visit or treatment. Aquila is preparing to enter large markets for the companion animal and food production sectors.
“This new technology... opens up the possibility of using a simple and highly sensitive molecular test at the point-of-care for the diagnosis of malaria and other blood-borne infections.”
Chief Scientific Officer Mark Perkins, Foundation for Innovative New Diagnostics (FIND), Geneva, in a favourable assessment showing Aquila’s Accutas™ diagnostic system achieved results superior to current malaria testing systems.